デフォルト表紙
市場調査レポート
商品コード
1004517

世界の樹状細胞ワクチン市場(2020年~2027年)

Global Dendritic Cell Cancer Vaccines Market - 2020-2027

出版日: | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: 約2営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.41円
世界の樹状細胞ワクチン市場(2020年~2027年)
出版日: 2021年05月10日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

がん患者数の増加が世界の樹状細胞ワクチン市場の成長を牽引しています。治療法に対する需要の増加、抗がん剤の革新、技術の向上、がんの治療法に関する意識の高まり、医療費の増加などが市場成長を促進すると予測されています。

当レポートでは、世界の樹状細胞ワクチン市場を調査し、市場の概要、セグメント・地域別の市場規模および成長率の推移と予測、新型コロナウイルス感染症(COVID-19)の影響分析、市場成長の促進要因および抑制要因の分析、市場機会、価格および貿易動向、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 調査手法と範囲

  • 調査手法
  • 調査の目的と調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

  • 市場内訳:製品タイプ別
  • 市場内訳:エンドユーザー別
  • 市場内訳:地域別

第4章 市場力学

  • 市場影響要因
    • 促進要因
    • 抑制要因
    • 市場機会
    • 影響分析

第5章 業界分析

  • ファイブフォース分析
  • サプライチェーン分析
  • バリューチェーン分析
  • PEST分析
  • 価格分析
  • 規制分析
  • 償還分析
  • アンメットニーズ
  • 特許動向

第6章 新型コロナウイルス感染症(COVID-19)の影響分析

  • 新型コロナウイルス感染症(COVID-19)の影響分析
    • コロナ以前の市場シナリオ
    • 現在の市場シナリオ
    • コロナ以降の市場シナリオ
  • コロナ渦中の価格動向
  • 需給スペクトラム
  • コロナ渦中の市場に対する政府イニシアチブ
  • メーカーの戦略的イニシアチブ
  • 総論

第7章 世界の樹状細胞ワクチン市場:製品タイプ別

  • イントロダクション
  • 市場規模・前年比成長率の分析:製品タイプ別
  • 市場魅力指数:製品タイプ別
    • Provenge(Sipuleucel-T)
    • Apceden
    • CreaVax
    • その他

第8章 世界の樹状細胞ワクチン市場:エンドユーザー別

  • イントロダクション
  • 市場規模・前年比成長率の分析:エンドユーザー別
  • 市場魅力指数:エンドユーザー別
    • 大人
    • 小児
    • その他

第9章 世界の樹状細胞ワクチン療法市場:地域別

  • イントロダクション
  • 市場規模の分析・前年比成長率:地域別
  • 市場魅力指数:地域別
  • 北米
    • イントロダクション
    • 市場力学
    • 市場規模・前年比成長率:製品タイプ別
    • 市場規模・前年比成長率:エンドユーザー別
    • 市場規模・前年比成長率:国別
  • 欧州
    • イントロダクション
    • 市場力学
    • 市場規模・前年比成長率:製品タイプ別
    • 市場規模・前年比成長率:エンドユーザー別
    • 市場規模・前年比成長率:国別
  • 南米
    • イントロダクション
    • 市場力学
    • 市場規模・前年比成長率:製品タイプ別
    • 市場規模・前年比成長率:エンドユーザー別
    • 市場規模・前年比成長率:国別
  • アジア太平洋地域
    • イントロダクション
    • 市場力学
    • 市場規模・前年比成長率:製品タイプ別
    • 市場規模・前年比成長率:エンドユーザー別
    • 市場規模・前年比成長率:国別
  • 中東・アフリカ
    • イントロダクション
    • 市場力学
    • 市場規模・前年比成長率:製品タイプ別
    • 市場規模・前年比成長率:エンドユーザー別
    • 市場規模・前年比成長率:国別

第10章 競合情勢

  • 競合シナリオ
  • 市場ポジショニング/株式分析
  • 合併・買収の分析

第11章 企業プロファイル

  • Biffa Group
    • 企業概要
    • 製品ポートフォリオ
    • 主なハイライト
    • 財務情勢
  • 3M Company
  • Activarti
  • Argos Therapeutics
  • Bellicum Pharmaceuticals
  • Elios Therapeutics
  • ImmunoCellular Therapeutics
  • Medigene
  • Merck & Co
  • Northwest Biotherapeutics

第12章 重要考察

第13章 DataM Intelligenceについて

目次

Market Overview

The global dendritic cell cancer vaccines market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).

Cancer treatment vaccines are made up of cancer cells, parts of cancer cells or antigens. These are made to recognize proteins on specific cancer cells. These cells help the immune system to recognize and attack those cancer cells. These vaccines might eventually help stop cancer growth, prevent cancer from coming back, and destroy cancer cells left behind after other treatments. Monocytes are extracted from the bloodstream of patients and cultured with synthetic forms of selected cancer neoantigens to form mature dendritic cells carrying those neoantigens. These cells are then reinfused into the patient's blood circulation. These dendritic cells help the immune system to recognize and attack abnormal cells, such as cancer cells. To make the vaccine, scientists grow dendritic cells alongside cancer cells in the lab. The vaccine then stimulates the immune system to attack cancer.

Market Dynamics

The growing incidence of cancer cases drives the global dendritic cell cancer vaccines market growth, increasing demand for therapies, improving technology such as drug innovations regarding cancer, upsurge in awareness about cancer and their available therapies, and increasing health care expenditure drive the market.

Growing incidence of cancer cases globally, is expected to drive the global Dendritic Cell Cancer Vaccines market growth.

As per the World Health Organization (WHO), Cancer is the second-most leading cause of death worldwide, accounting for over 18.1 million cases were diagnosed in 2018. In 2020, around 19 Mn new cancer cases were diagnosed across the world as per the WHO. Likewise, the American Cancer Society reported that 89,500 cases were diagnosed in the U.S. in 2020. Additionally, according to International Agency for Research on Cancer (IARC) estimates, by 2040, global cancer cases are expected to grow to 27.5 million new cancer cases worldwide. This number has led to an increase in the adoption of various cancer vaccines.

Stringent regulatory procedures are likely restricting the market growth.

As the increase in innovative strategies with novel products, a 2-way dialog with regulators is recommended on a case-by-case basis to justify the clinical development plan, taking into account specific quality issues related to the product's development. The rationale, background and justification for the planned development must be convincing when interacting with the regulatory authorities to enable drug developers and regulators to reach an agreement.

COVID-19 Impact Analysis

The COVID-19 pandemic has negatively impacted healthcare systems globally and majorly on the Personalized Cancer Vaccines. As per the article published in Cancer Connect 2020, doctors from Dana Farber Cancer Institute determined that during the COVID-19 pandemic, there was a 46% decrease in the diagnoses of the six most common cancer types - breast, colorectal, lung, pancreatic, gastric, and esophageal cancers. According to the Centers for Disease Control and Prevention (CDC) and many medical professional organizations recommended that cancer screening and other health prevention services, along with elective surgeries, be postponed unless the risks outweighed the benefits and secure the hospital infrastructure for the treatment of COVID-19 patients. Thus, the COVID-19 pandemic has impacted the On-going clinical trials too. However, the situation is expected to improve gradually.

Segment Analysis

Based on the Product Type, the global dendritic cell cancer vaccines market is segmented into Provenge (Sipuleucel-T), Apceden, CreaVax and Others

Provenge (Sipuleucel-T) accounts the largest share of the market.

Provenge (Sipuleucel-T) is a first approved dendritic cell cancer vaccine used to treat metastatic prostate cancer. It is used in patients with few or no symptoms and whose cancer is castration-resistant. It is made from a patient's immune cells that have been treated in the laboratory with GM-CSF (a type of growth factor) and a protein found on prostate cancer cells. Sipuleucel-T helps the immune system to kill prostate cancer cells, is a type of cellular adoptive immunotherapy. Also called APC8015 and Provenge. For instance, Sipuleucel-T was approved by the FDA on April 29, 2010, for the treatment of asymptomatic or less symptomatic metastatic castrate-resistant prostate cancer developed by Dendreon Corporation.

Based on End-users, the global Dendritic Cell Cancer Vaccines market is segmented into Pediatrics, Adults and Others

Dendritic cell vaccine treatment has been performed targeting many different types of tumor entities, most of which belong to types of cancer typically occurring in adults like melanoma, renal cell carcinoma, breast, colon, and prostate cancer, and Malignant glioma has also gained considerable attention in the field. This tumor is a tumor entity relevant also in pediatric oncology.

Geographical Analysis

North America region holds the largest market share global Dendritic Cell Cancer Vaccines market

North America holds the largest market in the global cancer stem cells market due to the high incidence of cancer, according to the International Agency for Research on Cancer (IARC), which claims 13 million new cancer cases worldwide. The World Cancer Report provides that the incidence rate of new cancer cases is increased by 50% to 15 million in 2020. The existence of a highly developed healthcare system, the high degree of acceptance by medical practitioners of novel chemotherapy and immunotherapy methods, the total availability of advanced technological tools, FDA approval of new drugs and also the presence of a vast number of organizations engaged in R&D activities related to cancer vaccines.

The Asia Pacific is expected to be the fastest-growing market over the forecast period owing to increasing prevalence rate, increasing focus on preventive care, and government initiatives promoting technological innovations. For instance, Capital Medical University Collaborated with Duke University conducting early Phase 1 study on personalized vaccine generated by Autologous Dendritic Cells Pulsed with Autologous Whole Tumor Cell Lysate to treat Advanced Solid Tumor Patients.

Competitive Landscape

The Global Dendritic Cell Cancer Vaccines Market is quite competitive with some key competitors like 3M Company, Activarti, Argos Therapeutics, Bellicum Pharmaceuticals, Dendreon Corporation, Elios Therapeutics. ImmunoCellular Therapeutics, Medigene, Merck & co, Northwest Biotherapeutics. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, contributing to the market's growth globally. For instance, On June 2, 2020, Northwest Biotherapeutics Inc, developed DCVax personalized immune therapy for solid tumor cancers is under Phase I/II trial of DCVax-Direct for all types of inoperable solid tumors.

Dendreon Corporation

Overview: Dendreon is a biotechnology company headquartered in California. Its lead product, Provenge, known generically as sipuleucel-T, is immunotherapy for prostate cancer and consists of a mixture of the patient's blood cells (autologous, with dendritic cells thought to be the most important) that have been incubated with the Dendreon PAP-GM-CSF fusion protein. In 2017, Dendreon resumed operations as a standalone company following an acquisition by Sanpower Group for $819.9 million.

Product Portfolio: Dendreon aims to stay at the forefront of development, manufacturing, and commercialization of immunotherapies that harness the power of the body's immune system to help extend patients' lives.

Key developments: P11-3 (STAMP)- A randomized, open-label, Phase 2 Trial of sipuleucel-T with concurrent versus sequential administration of abiraterone acetate plus prednisone in men with metastatic castrate resistant prostate cancer (mCRPC).

Why Purchase the Report?

  • Visualize the composition of the Dendritic Cell Cancer Vaccines Market segmentation by Product type, End-users, and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in Dendritic Cell Cancer Vaccines Market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of Dendritic Cell Cancer Vaccines Market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global Dendritic Cell Cancer Vaccines Market report would provide an access to an approx. 53 market data table, 43 figures and 240 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1. Global Dendritic Cell Cancer Vaccines Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Dendritic Cell Cancer Vaccines Market - Market Definition and Overview

3. Global Dendritic Cell Cancer Vaccines Market- Executive Summary

  • 3.1. Market snippet by Product Type
  • 3.2. Market Snippet by End-users
  • 3.3. Market Snippet by Region

4. Global Dendritic Cell Cancer Vaccines Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing prevalence of Cancer cases
    • 4.1.2. Restraints:
      • 4.1.2.1. Stringent regulatory procedures
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Dendritic Cell Cancer Vaccines Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Unmet Needs

6. Global Dendritic Cell Cancer Vaccines Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Dendritic Cell Cancer Vaccines Market - By Product type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product type
  • 7.3. Market Attractiveness Index, By Product type
    • 7.3.1. Provenge (Sipuleucel-T) *
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Apceden
    • 7.3.3. CreaVax
    • 7.3.4. Others

8. Global Dendritic Cell Cancer Vaccines Market - By End-users

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users segment
  • 8.3. Market Attractiveness Index, By End-users Segment
    • 8.3.1. Adults*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Pediatrics
    • 8.3.3. Others

9. Global Dendritic Cell Cancer Vaccines Market - By Region

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 9.3. Market Attractiveness Index, By Region
  • 9.4. North America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End -users
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. U.S.
      • 9.4.5.2. Canada
      • 9.4.5.3. Mexico
  • 9.5. Europe
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End -users
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. Germany
      • 9.5.5.2. U.K.
      • 9.5.5.3. France
      • 9.5.5.4. Italy
      • 9.5.5.5. Spain
      • 9.5.5.6. Rest of Europe
  • 9.6. South America
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End -users
    • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.6.5.1. Brazil
      • 9.6.5.2. Argentina
      • 9.6.5.3. Rest of South America
  • 9.7. Asia Pacific
    • 9.7.1. Introduction
    • 9.7.2. Key Region-Specific Dynamics
    • 9.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
    • 9.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.7.5.1. China
      • 9.7.5.2. India
      • 9.7.5.3. Japan
      • 9.7.5.4. Australia
      • 9.7.5.5. Rest of Asia Pacific
  • 9.8. Middle East and Africa
    • 9.8.1. Introduction
    • 9.8.2. Key Region-Specific Dynamics
    • 9.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users
    • 9.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

10. Global Dendritic Cell Cancer Vaccines Market - Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Global Dendritic Cell Cancer Vaccines Market - Company Profiles

  • 11.1. Dendreon Corporation*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. 3M Company,
  • 11.3. Activarti,
  • 11.4. Argos Therapeutics,
  • 11.5. Bellicum Pharmaceuticals,
  • 11.6. Elios Therapeutics.
  • 11.7. ImmunoCellular Therapeutics,
  • 11.8. Medigene,
  • 11.9. Merck & Co,
  • 11.10. Northwest Biotherapeutics

LIST NOT EXHAUSTIVE

12. Global Dendritic Cell Cancer Vaccines Market - Premium Insights

13. Global Dendritic Cell Cancer Vaccines Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us